李瑞雪　吴飞　张继全

[摘要] 目的 建立总皂苷含量测定方法和HPLC指纹图谱分析方法，对不同产地香加皮药材进行质量评价。 方法 采用紫外可见分光光度法，以杠柳苷C（PSA）为对照品，建立香加皮药材中总皂苷的含量测定方法；同时建立香加皮药材HPLC指纹图谱。对12批不同产地的香加皮中总皂苷进行含量测定，建立指纹图谱，计算相似度，采用SPSS软件对两类数据进行聚类分析。 结果 以5%香草醛-冰醋酸显色体系，检测波长为480 nm，12批药材中总皂苷含量在170～250 mg/g之间，差异较大；采用Capcell Pak C18色谱柱，流动相乙腈-0.2%甲酸水溶液梯度洗脱，检测波长263 nm，香加皮药材指纹图谱共标定25个共有峰，除1批样品外，其余样品相似度均在0.9以上。对皂苷含量及相似度数据进行聚类分析，结果显示，12批香加皮主要分为两类，高含量组和低含量组。 结论 建立的含量测定结合指纹图谱分析方法可以更好地用于香加皮的质量评价。

[关键词] 香加皮；紫外分光光度法；HPLC指纹图谱；质量评价

[中图分类号] R961 [文献标识码] A [文章编号] 1673-7210（2017）08（a）-0033-05

[Abstract] Objective To set up a simple and accurate method for the determination and evaluatation of Cortex Periplocae by UV-visible sepctrophotomery and HPLC fingerprint. Methods Determine the contents of 12 batches of Cortex Periplocae with periploside C （PSA） as the reference substance by UV-visible sepctrophotomery， meanwhile establish HPLC fingerprint and calculate the similarity. All data was analyzed by the SPSS statistical software. Results Determine the contents of 12 batches of Cortex Periplocae by 5% vanillin-glacial acetic acid with the detection wavelength at 480 nm. There was a significant difference in contents that ranged from 170 to 250 mg/g. HPLC analysis was performed on a Capcell Pak C18 column with the detection wavelength at 263 nm. The mobile phase was water containing 0.2% formic acid and acetonitrile in the gradient mode. 25 pesks were selected as the common peaks and the similarities were above 0.9 besides batch 7. Based on the results of quantification and fingerprint analysis， the results indicated that the 12 batches cortex periplocae divided into 2 classes： high and low content. Conclusion The established HPLC fingerprint and quantitative analysis methods can be used efficiently in the quality control of Cortex Periplocae.

[Key words] Cortex Periplocae； UV sepctrophotomery； HPLC fingerprint； Quality assessment

香加皮（Cortex Periplocae）為萝摩科植物杠柳（Periploca sepium Bunge）的根皮，又被称为北五加皮、杠柳皮或者香五加皮。最早载于《神农本草经》[1]，《中国药典》也均有收载，其功能祛风湿、强筋骨，用于心悸气短、下肢水肿、风寒湿痹、腰膝酸软[2]。

市场上香加皮与南五加皮混用情况比较严重，给临床用药带来困扰[3-4]。《中国药典》2015年版中以4-甲氧基水杨醛作为药材的含量控制指标[5]，也不能满足当前以C21甾体苷类成分为目标[6-8]的一些新药开发研究需求。……